文献速递重症综合管理与镇静镇痛心脑血管急症

心脏骤停后目标温度管理期间两种镇静方案的比较

Comparison of two sedation regimens during targeted temperature management after cardiac arrest.
PubMed 文献 · Resuscitation · 2018-03-16
一句话结论心脏骤停后目标温度管理期间,丙泊酚-瑞芬太尼较咪达唑仑-芬太尼觉醒更早、无呼吸机天数更多,但出院生存与神经预后无差异。

本研究比较心脏骤停后接受目标温度管理的昏迷幸存者中两种镇静方案:丙泊酚-瑞芬太尼(P2期)与咪达唑仑-芬太尼(P1期),除镇静和神经肌肉阻滞剂使用外管理方案不变。共纳入460例(P2期134例,P1期326例),两期CAHP评分无显著差异。两期均有60%患者觉醒,但P2期中位觉醒时间2.5小时(IQR 1-9)显著短于P1期17小时(IQR 7-60),延迟觉醒(>48小时)比例P2期6% vs P1期29%(P<0.001),调整后P2期延迟觉醒OR 0.08(95%CI 0.03-0.2,P<0.001)。P2期无呼吸机天数更多(25 vs 24天,P=0.007),第28天内无儿茶酚胺天数更低,但出院生存和良好神经预后无差异。

要点

  • 心脏骤停后目标温度管理期间,丙泊酚-瑞芬太尼组中位觉醒时间2.5小时(IQR 1-9),显著短于咪达唑仑-芬太尼组的17小时(IQR 7-60)。
  • 延迟觉醒(>48小时)比例丙泊酚-瑞芬太尼组6% vs 咪达唑仑-芬太尼组29%(P<0.001),调整后OR 0.08(95%CI 0.03-0.2,P<0.001)。
  • 丙泊酚-瑞芬太尼组无呼吸机天数更多(25 vs 24天,P=0.007),第28天内无儿茶酚胺天数更低。
  • 两期出院生存和良好神经预后无显著差异,且两期均有60%患者觉醒(81/134 vs 194/326,P=0.85)。
  • 两期基线严重程度CAHP评分无显著差异(P=0.93),除镇静和神经肌肉阻滞剂外管理方案不变。

适用人群与场景

  • 心脏骤停后接受目标温度管理的昏迷幸存者,共460例(丙泊酚-瑞芬太尼期134例,咪达唑仑-芬太尼期326例)。

诊断标准与关键阈值

  • 觉醒定义为停止镇静后发生;延迟觉醒定义为再升温结束停止镇静后超过48小时才觉醒。
  • 基线严重程度采用心脏骤停医院预后(CAHP)评分评估。

处置流程与药物剂量

  • 丙泊酚-瑞芬太尼方案(P2期)与咪达唑仑-芬太尼方案(P1期)比较,除镇静和神经肌肉阻滞剂使用外管理方案不变。
  • 再升温结束时停止镇静,从停止镇静起测量觉醒时间。

研究设计与关键结果

  • 研究比较两个时期(P2期丙泊酚-瑞芬太尼 vs P1期咪达唑仑-芬太尼)的镇静方案,纳入460例(P2期134例,P1期326例)。
  • 两期CAHP评分无显著差异(P=0.93)。
  • 两期均有60%患者觉醒(81/134 vs 194/326,P=0.85)。
  • 中位觉醒时间P2期2.5小时(IQR 1-9)vs P1期17小时(IQR 7-60)。
  • 延迟觉醒(>48小时)比例P2期6% vs P1期29%(P<0.001);调整后P2期延迟觉醒OR 0.08(95%CI 0.03-0.2,P<0.001)。
  • P2期无呼吸机天数更多(25 vs 24天,P=0.007),第28天内无儿茶酚胺天数更低。
  • 出院生存和良好神经预后两期无显著差异。

证据类型、等级与局限

  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在心脏骤停后目标温度管理期间,作者认为使用丙泊酚-瑞芬太尼镇静与更早觉醒和更多无呼吸机天数相关,但出院生存和良好神经预后无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Although guidelines on post-resuscitation care recommend the use of short-acting agents for sedation during targeted temperature management (TTM) after cardiac arrest (CA), the potential advantages of this strategy have not been clinically demonstrated.

METHODS: We compared two sedation regimens (propofol-remifentanil, period P2, vs midazolam-fentanyl, period P1) among comatose TTM-treated CA survivors. Management protocol, apart from sedation and neuromuscular blockers use, did not change between the two periods. Baseline severity was assessed with Cardiac-Arrest-Hospital-Prognosis (CAHP) score. Time to awakening was measured starting from discontinuation of sedation at the end of rewarming. Awakening was defined as delayed when it occurred after more than 48 h.

RESULTS: 460 patients (134 in P2, 326 in P1) were included. CAHP score did not significantly differ between P2 and P1 (P = 0.93). Sixty percent of patients awoke in both periods (81/134 vs. 194/326, P = 0.85). Median time to awakening was 2.5 (IQR 1-9) hours in P2 vs. 17 (IQR 7-60) hours in P1. Awakening was delayed in 6% of patients in P2 vs. 29% in P1 (p < 0.001). After adjustment, P2 was associated with significantly lower odds of delayed awakening (OR 0.08, 95% CI 0.03-0.2; P < 0.001). Patients in P2 had significantly more ventilator-free days (25 vs. 24 days; P = 0.007), and lower catecholamine-free days within day 28. Survival and favorable neurologic outcome at discharge did not differ across periods.

CONCLUSIONS: During TTM following resuscitation from CA, sedation with propofol-remifentanil was associated with significantly earlier awakening and more ventilator-free days as compared with midazolam-fentanyl.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Paul M, Bougouin W, Dumas F, et al. Comparison of two sedation regimens during targeted temperature management after cardiac arrest. Resuscitation. 2018. PMID: 29555261. doi:10.1016/j.resuscitation.2018.03.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。